exhibit A

Agreement of Joint Filing

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of ArriVent Biopharma, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

Date:      November 11, 2024

	SOFINNOVA VENTURE PARTNERS XI, L.P., a Delaware Limited Partnership

	By:	SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership
	Its:	General Partner

	By:	SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
	Its:	General Partner

	By:	/s/ Nathalie Auber
		Nathalie Auber
		Attorney-in-Fact

	SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership

	By:	SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company
	Its:	General Partner

	By:	/s/ Nathalie Auber
		Nathalie Auber
		Attorney-in-Fact

	SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company

	By:	/s/ Nathalie Auber
		Nathalie Auber
		Attorney-in-Fact

	DR. JAMES I. HEALY
	DR. MAHA KATABI

	By:	/s/ Nathalie Auber
		Nathalie Auber
		Attorney-in-Fact

*Executed pursuant to a Power of Attorney already on file with the appropriate agencies.

ArriVent BioPharma, Inc. SCHEDULE 13G/A